Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Carbetocin · ACP-101, FE-992097

Peptide · Agonist of oxytocin receptor (OXTR) · developed by ACADIA Pharmaceuticals

Phase 3 Most advanced trial

ACAD Developer

1 Registered trials

What is Carbetocin?

Carbetocin is a long-acting synthetic oxytocin agonist that binds and activates oxytocin receptors on uterine smooth muscle.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ACP-101, FE-992097, LV-101
Drug type: Peptide
Targets: oxytocin receptor (OXTR)
Mechanism: Agonist of oxytocin receptor (OXTR)
Pathways: uterine contraction
Therapy area: Endocrine
Developer: ACADIA Pharmaceuticals Inc. (ACAD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 88TWF8015Y

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06173531	Phase 3	Hyperphagia in Prader-Willi Syndrome	Active not recruiting	ACAD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hyperphagia in Prader-Willi Syndrome

More from ACADIA Pharmaceuticals

Pimavanserin FDA approved ACP-044 Phase 2 ACP-104 Phase 2 ACP-204 Phase 3 ACP-211 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACAD page.

Follow ACAD, the company behind Carbetocin

See ACAD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACAD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z